BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors-Reference-Cited by-同舟云学术

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors

Published:2017-04 Issue:2 Volume:6 Page:95-99
ISSN:2045-0907
Container-title:CNS Oncology
language:en
Short-container-title:CNS Oncology

Author:

Roque Ashley¹²,Odia Yazmin¹²

Affiliation:

1. Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA

2. Department of Neurology, Columbia University Medical School, New York, NY, USA

Abstract

We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cns-2016-0034

Reference13 articles.

1. Introduction

2. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up

3. Surgical Approaches

4. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

5. Craniopharyngiomas of Adamantinomatous Type Harbor β-Catenin Gene Mutations

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression;Acta Neuropathologica Communications;2024-08-10

2. BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study;European Journal of Endocrinology;2024-08

3. Approach to the Patient: New Era Emerges for Craniopharyngioma Management;The Journal of Clinical Endocrinology & Metabolism;2024-07-23

4. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature;Journal of Endocrinological Investigation;2024-05-02

5. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review;CNS Oncology;2024-04-23